MedTrace Logo

MELanoma Brain Metastasis Treated With CYberknife

NCT07691255 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-07-08

No results posted yet for this study

Summary

Melanoma is a type of cancer that can spread to the brain, making the disease harder to treat and worsening both survival and quality of life.

In recent years, treatments have improved significantly thanks to advances in surgery, radiotherapy, immunotherapy, and targeted therapy. These new treatments have greatly increased survival rates for patients with metastatic melanoma.

This study focuses on stereotactic radiosurgery, a highly precise form of radiotherapy used to treat brain metastases. Researchers want to better understand how this treatment works when combined with immunotherapy or targeted therapy, and whether the timing and sequence of treatments can improve outcomes.

Between 2026 and 2028, patients treated at the IEO for melanoma brain metastases will be observed and their clinical data collected. The goal is to improve future treatment strategies and help doctors choose the best therapeutic approach for each patient.

Conditions

  • Melanoma (Skin Cancer)

Sponsors & Collaborators

  • Accuray Incorporated

    collaborator INDUSTRY

  • European Institute of Oncology

    lead OTHER

Principal Investigators

  • Samantha Dicuonzo, MD · European Institute of Oncology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2030-01-01
Completion
2030-01-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07691255 on ClinicalTrials.gov